Clinical effect not specified
Source: DDInter
General Anesthetic · Anaesthetic
Also known as AErrane
Isoflurane is a halogenated methyl ethyl ether volatile anesthetic with a MAC of 1.15% that potentiates GABA-A receptor-mediated inhibition and attenuates glutamate-mediated excitation. It produces dose-dependent decreases in mean arterial pressure primarily through peripheral vasodilation, with relatively preserved cardiac output compared to halothane. Isoflurane undergoes minimal hepatic metabolism (0.2%), producing negligible fluoride ion release and making it the least hepatotoxic of the halogenated agents.
May depress neonatal respiration if used during delivery.
Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.
Clinical effect not specified
Source: DDInter
Drug interaction classified as: others.
Source: DDInter
Clinical effect not specified
Source: DDInter
.
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Increased neuromuscular blockade from competitive blockers.
Source: KDT 7e · p347-359
Enhanced neuromuscular blockade.
The dose of competitive neuromuscular blocker may need to be 1/3–1/2 of the figure given for opioid/nitrous oxide + oxygen anaesthesia.
Source: KDT 7e · Table 25.2 footnote
Decreased effectiveness of isoflurane.
Not explicitly stated.
Source: DDInter
Phase II blockade by succinylcholine; malignant hyperthermia.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-13 · House clinical team